Capvaxive - A 21-Valent Pneumococcal Conjugate Vaccine

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2024年 / 66卷 / 1713期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：10
相关论文
共 50 条
  • [1] FDA approves 21-valent pneumococcal vaccine
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (08) : 572 - 572
  • [2] Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach
    Mueller, Peter P.
    Tajima, Atsushi
    Cassell, Kelsie
    Matsuki, Taizo
    Cossrow, Nicole
    Yi, Zinan
    Johnson, Kelly D.
    Owusu-Edusei, Kwame
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 136 - 145
  • [3] EVALUATING THE POTENTIAL HEALTH AND ECONOMIC IMPACT OF V116, AN ADULT SPECIFIC 21-VALENT PNEUMOCOCCAL CONJUGATE VACCINE, ON INVASIVE PNEUMOCOCCAL DISEASE IN SWITZERLAND
    Simuzingili, M.
    Cossrow, N.
    Favre-Bulle, A.
    Mutschler, T.
    Johnson, K. D.
    Owusu-Edusei, K.
    VALUE IN HEALTH, 2024, 27 (12) : S78 - S78
  • [4] Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study
    Haranaka, Miwa
    Yono, Makoto
    Kishino, Hiroyuki
    Igarashi, Rie
    Oshima, Nobuyuki
    Sawata, Miyuki
    Platt, Heather Loryn
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [5] ESTIMATING THE POTENTIAL LIFETIME HEALTH AND ECONOMIC IMPACT OF V116, AN ADULT SPECIFIC 21-VALENT PNEUMOCOCCAL CONJUGATE VACCINE, ON INVASIVE PNEUMOCOCCAL DISEASE IN GREECE
    Yi, Z.
    Gountas, I
    Tsoumani, E.
    Trimis, G.
    Johnson, K. D.
    Owusu-Edusei, K.
    VALUE IN HEALTH, 2024, 27 (12) : S87 - S87
  • [6] Use of 21-Valent Pneumococcal Conjugate Vaccine Among US Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024
    Kobayashi, Miwako
    Leidner, Andrew J.
    Gierke, Ryan
    Farrar, Jennifer L.
    Morgan, Rebecca L.
    Campos-Outcalt, Doug
    Schechter, Robert
    Poehling, Katherine A.
    Long, Sarah S.
    Loehr, Jamie
    Cohen, Adam L.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2024, 73 (36): : 793 - 798
  • [7] Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
    Ximenes, Raphael
    Simmons, Alison E.
    Gebretekle, Gebremedhin B.
    Nam, Austin
    Wong, Eva
    Salvadori, Marina I.
    Golden, Alyssa R.
    Sander, Beate
    Hildebrand, Kyla J.
    Tunis, Matthew
    Tuite, Ashleigh R.
    VACCINE, 2025, 54
  • [8] EVALUATING THE POTENTIAL HEALTH AND ECONOMIC IMPACT OF V116, AN ADULT SPECIFIC 21-VALENT PNEUMOCOCCAL CONJUGATE VACCINE, ON INVASIVE PNEUMOCOCCAL DISEASE IN THE UNITED STATES
    Yi, Z.
    Elbasha, E.
    Owusu-Edusei, K.
    VALUE IN HEALTH, 2024, 27 (06) : S96 - S96
  • [9] Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models
    Curry, Stephanie
    Kaufhold, Robin M.
    Monslow, Morgan A.
    Zhang, Yuhua
    McGuinness, Debra
    Kim, Ellie
    Nawrocki, Denise K.
    McHugh, Patrick M.
    Briggs, Marie L.
    Smith, William J.
    He, Jian
    Joyce, Joseph G.
    Skinner, Julie M.
    VACCINE, 2023, 41 (04) : 903 - 913
  • [10] Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
    Altawalbeh, Shoroq M.
    Wateska, Angela R.
    Nowalk, Mary Patricia
    Lin, Chyongchiou J.
    Harrison, Lee H.
    Schaffner, William
    Zimmerman, Richard K.
    Smith, Kenneth J.
    VACCINE, 2024, 42 (12) : 3024 - 3032
12345